Creative Medical Technology Holdings (CELZ) Consolidated Net Income (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Consolidated Net Income of -$1.4 million for Q1 2026, up 14.31% year-over-year from -$1.2 million in Q1 2025, and up 37.05% quarter-over-quarter from -$2.2 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Consolidated Net Income (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Consolidated Net Income for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income rose 14.31% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$6.1 million (up 15.39% YoY), while the FY2025 annual figure was -$6.3 million, up 4.21% from the prior year.
- Consolidated Net Income improved to -$1.4 million in Q1 2026 per CELZ's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$982339.0 in Q3 2022 and bottomed at -$6.2 million in Q4 2022.
- Historically, Consolidated Net Income has averaged -$1.8 million across 5 years, with a median of -$1.4 million in 2026.
- Annual changes were most pronounced in 2022 — Consolidated Net Income sank 104.15% — and 2023, when it jumped 72.99%.
- Creative Medical Technology Holdings' Consolidated Net Income stood at -$6.2 million in 2022, then surged by 72.99% to -$1.7 million in 2023, then tumbled by 77.34% to -$3.0 million in 2024, then climbed by 25.09% to -$2.2 million in 2025, then surged by 37.05% to -$1.4 million in 2026.
- Business Quant data shows CELZ's Consolidated Net Income at -$1.4 million in Q1 2026, -$2.2 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | -1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.51 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | -1.23 Mn |
| Mar 31, 2025 | -1.64 Mn |
| Dec 31, 2024 | -2.98 Mn |
| Sep 30, 2024 | -1.04 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | -1.68 Mn |
| Sep 30, 2023 | -1.45 Mn |
| Jun 30, 2023 | -1.10 Mn |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | -6.22 Mn |
| Sep 30, 2022 | -982,339.00 |
| Jun 30, 2022 | -1.79 Mn |
| Mar 31, 2022 | -1.15 Mn |
| Dec 31, 2021 | -3.88 Mn |
| Sep 30, 2021 | -1.84 Mn |